MIRATI Trademark

Trademark Overview

On Thursday, May 27, 2021, a trademark application was filed for MIRATI with the United States Patent and Trademark Office. The USPTO has given the MIRATI trademark a serial number of 90739492. The federal status of this trademark filing is REGISTERED as of Tuesday, April 4, 2023. This trademark is owned by Mirati Therapeutics, Inc.. The MIRATI trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the prevention and/or treatment of cancer; pharmaceutical preparations for use in oncology
mirati

General Information

Serial Number90739492
Word MarkMIRATI
Filing DateThursday, May 27, 2021
Status700 - REGISTERED
Status DateTuesday, April 4, 2023
Registration Number7019942
Registration DateTuesday, April 4, 2023
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, February 15, 2022

Trademark Statements

Description of MarkThe mark consists of a stylized term MIRATI.
Goods and Servicespharmaceutical preparations for the prevention and/or treatment of cancer; pharmaceutical preparations for use in oncology

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 25, 2021
Primary Code005
First Use Anywhere DateTuesday, December 13, 2022
First Use In Commerce DateTuesday, December 13, 2022

Trademark Owner History

Party NameMirati Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameMirati Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameMirati Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Monday, May 31, 2021NEW APPLICATION ENTERED
Wednesday, August 25, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 1, 2021ASSIGNED TO EXAMINER
Monday, November 8, 2021NON-FINAL ACTION WRITTEN
Monday, November 8, 2021NON-FINAL ACTION E-MAILED
Monday, November 8, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 20, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 20, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 20, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 10, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 10, 2022ASSIGNED TO LIE
Wednesday, January 26, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 15, 2022PUBLISHED FOR OPPOSITION
Tuesday, February 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 12, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 11, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, October 11, 2022SOU EXTENSION 1 FILED
Tuesday, October 11, 2022SOU EXTENSION 1 GRANTED
Thursday, October 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 2, 2023TEAS STATEMENT OF USE RECEIVED
Monday, January 2, 2023USE AMENDMENT FILED
Monday, January 30, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, February 4, 2023STATEMENT OF USE PROCESSING COMPLETE
Monday, February 27, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, February 28, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, April 4, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 4, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, June 25, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, June 25, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 25, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Related Keywords

mirati pharmaceutical preparations oncology cancer prevention treatment